Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06647160

Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control

The goal of this randomised controlled clinical trial is to compare the effects of a new type of concentric columnar microstructure lens and single-vision spectacle lenses on myopia progression in Chinese children aged 8-11 years with refractive error ranging from -0.50D to -6.00D. Participants will wear spectacles and receive follow-up examinations every half year.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Myopia, Progressive Eye Diseases Myopia Myopia, Degenerative Refractive Errors

Age range

8 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, 510060, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 8 to 11 years;
  • Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -6.00 to -0.50 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.50 D;
  • Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen).
  • The intraocular pressure of 10 to 21mmHg.
  • Volunteer to participate in this clinical trial with signature of the informed consent form.

Exclusion criteria

  • History of eye injury or intraocular surgery;
  • Clinically abnormal slit-lamp findings
  • Abnormal fundus examination
  • Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function;
  • Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses);
  • Participation of the drug clinical trial within three month and the device clinical trial within one month;
  • Only one eye meets the inclusion criteria;
  • Unable to have regular follow-up
  • Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursingproducts), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc.

Treatment and study plan

Blue star MAX-5 spectacle lens

Device

The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.

Single-vision spectacle lens

Device

The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.

Primary outcomes

  1. Changes of spherical equivalent refraction (SER) at two years

    Time frame: 2 years

    The difference of SER (Diopter) at two years compared with baseline SER. SER will be measured after cycloplegia.

Secondary outcomes

  1. Changes of axial length (AL) at two years

    Time frame: 2 years

    The difference of AL (mm) at two years compared with baseline AL. AL will be measured by IOLMaster-700.

  2. Visual scale score at two years

    Time frame: 2 years

    Visual scale score measured by the Chinese version of the pediatric refractive error profile2 (PREP2) is scaled from 0 (poor quality of life) to 100 (good quality of life).

  3. Incidence of adverse event during study period

    Time frame: 2 years

    Adverse event is a comprehensive qualitative outcome measure that will be evaluated based on the participants' symptoms and signs, intraocular pressure, slit lamp and fundus examinations, as well as lens and frame damage. The evaluation will be conducted every six months according to the predetermined definition of abnormalities in the above examinations.

Other outcomes

  1. Change of lens thickness (LT) at two years

    Time frame: 2 years

    The difference of LT (mm) at two years compared with baseline LT. LT will be measured by IOLMaster-700.

  2. Change of corneal power (CP) at two years

    Time frame: 2 years

    The difference of CP (diopter) at two years compared with baseline CP. CP will be measured by IOLMaster-700.

  3. Best corrected visual acuity at two years

    Time frame: 2 years

    Best corrected visual acuity will be measured at baseline and two years by EDTRS visual acuity chart.

  4. Binocular visual function at two years

    Time frame: 2 years

    Binocular visual function which is a qualitative outcome assessed by a series of tests will be measured every half year.

  5. Change of choroidal thickness at two years

    Time frame: 2 years

    The difference of Choroidal thickness (μm) at two years compared with baseline measure. Choroidal thickness will be measured by OCTA.

Sponsors and collaborators

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Other

Registry information

Official study title

Safety and Efficacy of Blue Star MAX-5 Lenses in Mvopia Control: A Randomized Controlled Clinical Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Oct 17, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.